Search

Displaying results 1341 - 1350 of 10000 in total
  1. Drug

    Esomeprazole

    go.drugbank.com/drugs/DB00736
    ApprovedInvestigational

    As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole's duration of antisecretory effect persists … Esomeprazole is the s-isomer of [DB00338], which is a racemate of the S- and R-enantiomer.

    Mixtures: OCAM PROTECT® 7.5 TABLETAS DE LIBERACIÓN RETARDADA, OCAM PROTECT ® 15 MG TABLETAS DE LIBERACION RETARDADAProducts: E-SOME, TABLETAS DE LIBERACIÓN RETARDADA.
  2. Drug

    Valine

    go.drugbank.com/drugs/DB00161
    ApprovedInvestigationalNutraceutical

    It is a precursor in the penicillin biosynthetic pathway.

    Mixtures: Clinimix E, Clinimix E
  3. Drug

    PRX-P4-003

    go.drugbank.com/drugs/DB33967
    Experimental

    PRX-P4-003 is under investigation in clinical trial NCT04638803 (A Phase 0, Open-Label, Crossover Microdose Pharmacokinetic Study of PRX-P4-003 in Healthy Volunteers).

  4. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). … It is metabolized to its biologically active diacid form, trandolaprilat, in the liver.

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Carbocisteine

    go.drugbank.com/drugs/DB04339
    ApprovedInvestigational

    Carbocisteine is a mucolytic drug that alleviates respiratory symptoms and infections by reducing the viscosity of mucus, allowing it to be expelled. … Individuals with COPD have a greater risk of pulmonary infection due to the growth and accumulation of viruses and bacteria in thick bronchial mucus.

    Mixtures: GUAYACOLATO DE GLICERILO - CARBOXIMETILCISTEINAProducts: SOLVELIN DE ANGELI
  6. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. … It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092).

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Fenobam

    go.drugbank.com/drugs/DB12931
    Investigational

    Fenobam is under investigation in clinical trial NCT00637221 (Open Label Study Investigating Safety and Efficacy of Fenobam anhydrous 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance

  9. Drug

    Pentazocine

    go.drugbank.com/drugs/DB00652
    ApprovedVet approved

    The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Phenaridine

    go.drugbank.com/drugs/DB09178
    ExperimentalIllicit

    Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue … to appear.